Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Addex Therapeutics Full Year twenty twenty five Financial Results and Corporate Update Conference Call and Webcast. At this time, all participants are in listen only mode. After the speakers' presentation, there will be the question and answer session. To ask a question during the session, you need to press 11 on your telephone keypad. You will then hear an automatic message advising your hand is raised. To withdraw a question, please press 11 again. If you wish to ask a question via the webcast, please use the Q and A box available on the webcast link anytime during the live event. Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Tim Dyer. Please go ahead. Thank you. Hello, everyone. I would like to thank you all for attending our twenty twenty five full year financial results conference call. I'm here with Misha Kalinichev, our head of translational science, who will provide an update on our r and d programs. I draw your attention to the press release and the financial statements issued earlier today, are available on our website. I also draw your attention to our disclaimer. We will be making certain forward looking statements that are based on the knowledge we have today. I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Misha who will review in more detail our mBluR5 negative allosteric modulator program for brain injury recovery and the GABA B positive allosteric modulator preclinical program for cough. I will then review our twenty twenty five full year financial results. Following that, we will open the call for q...